the aid library

LIST OPTIONS

Filter

1029

Sort by:

Direction:

Download (416)

View PDF (559)

Guidelines for the diagnosis and treatment of Chagas disease
recommended

World Health Organization WHO PAHO, WHO (2019) C_WHO

This document focuses on making recommendations for the diagnosis and treatment of Chagas disease, an infection caused by Trypanosoma cruzi, the protozoan agent of a systemic parasitic disease. Methodology: These clinical practice guidelines were prepared following the WHO handbook for guideline dev... more

Download (196)

View PDF (220)

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

Download (119)

View PDF (365)

Dengue virus: epidemiology, biology, and disease aetiology

Kumar Roy., S. and S. Bhattacharjee (2021) CC

Canadian Journal of Microbiology 25 June 2021 https://doi.org/10.1139/cjm-2020-0572

Download (124)

View PDF (539)

Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection.

Abras A., Ballart C., Fernández-Arévalo A., et al. Clinical Microbiology Reviews (2022) CC

Population movements have turned Chagas disease (CD) into a global public health problem. Despite the successful implementation of subregional initiatives to control vectorial and transfusional Trypanosoma cruzi transmission in Latin American settings where the disease is endemic, congenital CD (cCD... more

Download (81)

View PDF (443)

Health beliefs and health seeking behavior towards lymphatic filariasis morbidity management and disability prevention services in Luangwa District, Zambia: Community and provider perspectives

Maritim, P., A. Silumbwe, J.M. Zulu, et al. (2021) C2

Lymphatic filariasis (LF) infection if untreated results in fluid accumulation in the limbs or breasts (lymphedema) or genitalia (hydrocele) that is painful and causes great discomfort. Morbidity management and disability prevention (MMDP) strategies such as surgery for hydrocele, treatment of acute... more

Download (76)

View PDF (350)

Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis

World Health Organization WHO (2012) C_WHO

This report provides a review and analysis of the research landscape for three diseases – Chagas disease, human African trypanosomiasis and leishmaniasis – that disproportionately afflict poor and remote populations with limited access to health services. It represents the work of the disease re... more

Download (77)

View PDF (536)

Guidelines of Chagas Disease for the Diagnosis and Treatment

Luquetti, A.; Tavares, S. Pan American Health Organization PAHO - World Health Organization WHO (2019) C_WHO

he Pan American Health Organization (PAHO) would like to thank the group that developed these guidelines for the tremendous work, quick response, and commitment they demonstrated in this process. We would like to especially recognize the following doctors: Roberto Chuit, Jaime Altcheh, Alejandro Luq... more

Download (108)

View PDF (352)

Accelerating towards human African trypanosomiasis elimination: Issues and opportunities

Ozioko ,KU.; Okoye, CI.; Obiezue, RN.; Idika, IK.; Awudu, RA.; Ezewudo, BI.; Ezea, CO. (2019) CC

Human African trypanosomiasis (HAT) has been an alarming global public health issue. The disease affects mainly poor and marginalized people in low-resource settings and is caused by two subspecies of haemoflagellate parasite, Trypanosoma brucei and transmitted by tsetse flies. Progress made in HAT ... more

Download (164)

View PDF (201)

Interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions

World Health Organization WHO WHO (2019) C_WHO

An interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions was organized by the World Health Organization (WHO) Regional Office for the Eastern Mediterranean in Amman, Jordan, from 23 to 25 September 2018. The meeting w... more

Download (98)

View PDF (383)

Guide for the Medical, Veterinary and allied Professions

Bishop, G.; Durrheim, D.; Kloeck, P. et al. Department: Agriculture, Foresty and Fisheries - Republic of South Africa (2010) CC

Rabies is a disease of animals but too often the outcome is gauged in terms of human suffering and death. Despite this, in areas of the world where rabies is endemic there is often a lack of communication between veterinary and medical professionals, to the extent that the disease continues to thri... more

Download (179)

View PDF (196)

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended

World Health Organisation (WHO) (2023) C_WHO

The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys... more

Download (129)

View PDF (158)

Longlist of knowledge gaps in Planetary health

Royal Netherlands Academy of Arts and Sciences (2023) C2

The longlist of knowledge gaps is based on existing research agendas published in 2015 or later and expert input from reviewers of the first draft of the longlist. It only includes knowledge gaps focussing on a better understanding of the relationship between global environmental change and human h... more

Download (166)

View PDF (177)

Global vaccine market report 2022: a shared understanding for equitable access to vaccines

World Health Organisation (WHO) (2023) C_WHO

The report aims to capture lessons from the COVID-19 pandemic and to highlight the opportunity for more ambitious global action: expanding sustainable access to vaccines for all towards the Immunization Agenda 2030 and pandemic prevention, preparedness and response efforts. The report is organized i... more

Download (124)

View PDF (139)

Medical treatment of cystic echinococcosis: systematic review and meta-analysis

Velasco-Tirado, V.; Alonso-Sardón, M.; Lopez-Bernus, A. et al BMC Infectious Diseases (2018) C2

Cystic echinococcosis (CE) is a well-known neglected parasitic disease. However, evidence supporting the four current treatment modalities is inadequate, and treatment options remain controversial. The aim of this work is to analyse the available data to answer clinical questions regarding medical t... more

Download (79)

View PDF (83)

From Panic and Neglect to Investing in Health Security

The World Bank (2017) CC

Multiple pandemics, numerous outbreaks, thousands of lives lost and billions of dollars of national income wiped out—all since the turn of this century, in barely 17 years—and yet the world’s investments in pandemic preparedness and response remain woefully inadequate. We know by now that the ... more

Download (115)

View PDF (123)

Ending disease in Africa: vision, strategies and special initiatives, 2023-2030

World Health Organisation (WHO) (2023) C_WHO

While there has been real progress in addressing the burden of disease in the WHO African region, the COVID-19 pandemic has highlighted the link between health, economics and security, as the region saw decades of progress threatened, including positive trends in decreasing inequality. In the Africa... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (92)

View PDF (89)

Guidance on the use of mpox vaccines. Revised edition

Pan American Health Organisation PAHO (2024) CC

Smallpox eradication was certified in 1980. Mpox has been endemic in Central and West African countries since it was first detected in 1958 . It is a zoonosis; cases are often found close to tropical rainforests where various animals carry the orthopoxvirus that causes the disease. In endemic countr... more

Download (16)

View PDF (23)

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors 2023

World Health Organization WHO (2023) C_WHO

Download (24)

View PDF (21)

Kenya Asthma Management Guideline

Ministry of Health (2021) CC

Bonchial asthma is the most common chronic respiratory disease in the world. In Kenya, it has been estimated that about 7.5% of the Kenyan population, nearly 4 million people, are currently living with asthma. Many cases tend to be underdiagnosed and undertreated which leads to high levels of morbid... more

Guidelines for the diagnosis and treatment of Chagas disease recommended

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors recommended

Guidelines for the diagnosis and treatment of Chagas disease
recommended

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended